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Abstract
Introduction: In response to gamma-irradiation (IR)-induced double-strand DNA breaks, cells undergo cell-cycle
arrest, allowing time for DNA repair before reentering the cell cycle. G2/M checkpoint activation involves activation
of ataxia telangiectasia mutated (ATM)/ATM- and rad3-related (ATR) kinases and inhibition of Cdc25 phosphatases,
resulting in inhibition of Cdc2 kinase and subsequent G2/M cell-cycle arrest. Previous studies from our laboratory
showed that the G2/M checkpoint activation after IR exposure of MCF-7 breast cancer cells is dependent on the
activation of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) signaling. In the present studies, we
investigated the role of Ras-related C3 botulinum toxin substrate 1 (Rac1) guanosine triphosphatase (GTPase) in IR-
induced G2/M checkpoint response and ERK1/2 activation, as well as in cell survival after IR.
Methods: With Rac1-specific inhibitor, dominant negative mutant Rac1 (N17Rac1) and specific small interfering
RNA, the effect of Rac1 on IR-induced G2/M checkpoint response and ERK1/2 activation was examined in human
breast cancer cells. In addition, the effect of Rac1 on cell survival after irradiation was assessed by using Rac1-
specific inhibitor.
Results: IR exposure of MCF-7 breast cancer cells was associated with a marked activation of Rac1 GTPase.
Furthermore, inhibition of Rac1 by using specific inhibitor, dominant-negative Rac1 mutant, or specific siRNA
resulted in attenuation of IR-induced G2/M arrest and concomitant diminution of IR-induced activation of ATM,
ATR, Chk1, and Chk2 kinases, as well as phosphorylation of Cdc2-Tyr15. Moreover, Rac1 inhibition or decreased
Rac1 expression also abrogated IR-induced phosphorylation of mitogen-activated protein kinase kinase 1 and 2
(MEK1/2) and ERK1/2. Ultimately, inhibition of Rac1 markedly increased cellular sensitivity to IR exposure, which
involves induction of apoptosis.
Conclusion: Studies in this report suggest that Rac1 GTPase plays an essential role in the activation of IR-induced
ERK1/2 signaling and subsequent G2/M checkpoint response. Furthermore, results also support a role for Rac1 in
promoting cell survival after irradiation treatment.
Introduction
DNA damage by ionizing irradiation (IR) triggers rapid
activation of DNA-damage checkpoint response, result-
ing in either cell-cycle arrest that allows DNA repair or
induction of apoptosis, which eliminates seriously
damaged or deregulated cells [1]. Previous studies iden-
tified several intracellular signaling cascades, including
signalings mediated by ataxia telangiectasia-mutated
(ATM) and ATM- and rad3-related (ATR), in the acti-
vation of DNA-damage checkpoint response [2].
The G2/M cell-cycle checkpoint is tightly controlled
by the Cdc2/cyclin B complex, whose activity is required
for G2/M transition of the cell cycle [3]. Previous studies
identified the Cdc2-Tyr15 as a critical site involved in
G2/M-checkpoint control in response to DNA damage.
Cdc2-Tyr15 phosphorylation is induced and maintained
during radiation-induced G2/M arrest, and introduction
in fission yeast of a mutant Cdc2-Y15F, which cannot
be phosphorylated at the tyrosine 15 residue, completely
abolished DNA-damage-induced G2/M arrest [4-6].
Cdc2-Tyr15 is phosphorylated by Wee1 kinase, which
phosphorylates Cdc2 at Tyr15, and by Myt1 kinase,
which phosphorylates Cdc2 at Thr14 and, to a lesser
extent, at Tyr15 [7,8].
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Dephosphorylation of Cdc2-Tyr15 involves Cdc25
dual-specific phosphatases [9]. In response to DNA
damage, ATM and ATR kinases are rapidly activated
through phosphorylation, which, in turn, leads to the
phosphorylation/activation of their downstream targets
Chk1 and Chk2 kinases, respectively. Activation of Chk1
and Chk2 kinases results in phosphorylation of Cdc25,
leading to the subcellular sequestration, degradation,
and/or inhibition of the Cdc25 phosphatases that nor-
mally activate Cdc2/cyclin B at the G2/M boundary [10].
On cell transition from G2 to mitotic phase, histone
H3 is phosphorylated at Ser10, which is associated with
chromosome condensation before cell division [11].
Because both G2 and mitotic cells have 4N-DNA con-
tent and are not distinguishable from each other by pro-
pidium iodide staining, phosphorylation of H3-Ser10 in
4N-DNA content cells has been commonly used as a
specific marker indicative of mitotic cells [12]. Further-
more, previous studies indicate that the initial phosphor-
ylation of H3-Ser10 occurs in the late G2 phase but only
on the pericentromeric chromatin. As cells progress
through mitosis, the phosphorylation spreads along
chromosomes and is completed at the end of prophase
[13,14]. Thus, a gradual increase in H3-Ser10 phosphor-
ylation occurs from the beginning of mitosis to the end
of mitosis. In log-phase growing cells, phosphorylation
of H3-Ser10 in mitotic cells is detected in a wide range
with flow-cytometry analysis [15,16]. In response to irra-
diation-induced G2/M cell-cycle arrest, the phosphoryla-
tion of H3-Ser10 is suppressed in irradiated cells
because of the blockage of the G2/M transition of the
cell cycle [3,15,16].
Previous studies in a wide variety of cell types have
shown that IR exposure results in rapid activation of
MAPK family members, including ERK1/2, JNK, and
p38 [17,18]. Although p38g activation may be essential
in IR-induced G2/M arrest in HeLa and U2OS cells
[19], studies from our laboratory and others have
demonstrated that IR-induced ERK1/2 activation is
necessary for the activation of the G2/M checkpoint
response in MCF-7 breast cancer cells and that inhibi-
tion of ERK1/2 is associated with increased sensitivity to
DNA-damaging agents [16,20,21].
Ras-related C3 botulinum toxin substrate 1 (Rac1), a
member of the Rho family of small guanosine tripho-
sphatases (GTPases), has been shown to play a critical
role in the regulation of cytoskeleton reorganization,
cell migration, and cell survival [22]. Rac1 overexpres-
sion has been detected in many tumor types, including
breast, lung, and colon cancer [23-25]; and Rac1b, a
fast-cycling splice variant of Rac1, has been observed
to be highly expressed in some breast and colon can-
cers [25,26]. Through interaction with various down-
stream effectors, Rac1 has been shown to activate
numerous signaling pathways, including those
mediated by the members of the MAPK family [27]. In
response to various stimuli, previous studies showed
that Rac1 can activate ERK1/2 signaling via p21-acti-
vated kinases 1 and 2, which phosphorylate Raf1 and
MEK1 and facilitate the formation of the Raf/MEK/
ERK complex [28-30]. Other studies indicated that
Rac1 is involved in the activation of JNK and p38 sig-
naling in response to angiotensin II stimulation [31].
Although the regulation of Rac1 on cytoskeleton reor-
ganization and cell migration has been intensively
investigated, the contribution of Rac1 to cell-cycle reg-
ulation has remained largely unknown. A previous
study showed that expression of N17Rac1, a dominant-
negative mutant of Rac1, in log-phase growing Rat 2
fibroblast cells, resulted in G2/M cell-cycle arrest [32].
Furthermore, a recent report detected the presence of
Rac1 in the nucleus, and the level of nuclear Rac1 was
increased when cells were in late G2 phase [33]. This
evidence suggests a potential role for Rac1 in the regu-
lation of cell-cycle progression in proliferating cells.
In the present study, we examined the effect of Rac1
on the IR-induced G2/M checkpoint response in human
breast cancer cells. Results presented in this report indi-
cate that IR exposure of cells induces Rac1 activation
and that this is necessary for the activation of ERK1/2
signaling, subsequent G2/M checkpoint response, and
cell survival after IR.
Materials and methods
Cell culture and treatment
Human breast cancer cell lines MCF-7, T47D, ZR-75-1,
and MDA-MB-231 were obtained from American Type
Culture Collection (Manassas, VA, USA). MCF-7, T47D,
and ZR-75-1 cells were maintained in Dulbecco Modi-
fied Eagle medium containing 10% fetal bovine serum.
MDA-MB-231 cells were maintained in the Leibovitz L-
15 medium containing 10% fetal bovine serum. MCF-
10A is a nontumorigenic human mammary epithelial
cell line that was spontaneously immortalized previously
[34]. 76 N is a nontransformed line of primary human
mammary epithelial cells immortalized by human telo-
merase (hTERT) [35]. MCF-10A and 76 N cells are kind
gifts from Dr. Vimla Band (University of Nebraska Med-
ical Center). Both cell lines were maintained in Dana-
Farber Cancer Institute 1 growth medium (DFCI-1).
DFCI-1 medium consists of a-MEM/Ham nutrient mix-
ture F-12 (1:1, vol/vol) supplemented with epidermal
growth factor (12.5 ng/ml), triiodothyronine (10 nM),
Hepes (10 mM), ascorbic acid (50 μM), estradiol (2
nM), insulin (1 μg/ml), hydrocortisone (2.8 μM), ethano-
lamine (0.1 mM), phosphoethanolamine (0.1 mM),
transferrin (10 μg/ml), L-glutamine (2 mM), sodium
selenite (15 nM), cholera toxin (1 ng/ml), 1% fetal
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bovine serum, and bovine pituitary extract (35 μg/ml)
[35].
Rac1-specific inhibitor NSC23766 [36] was obtained
from Tocris Biosciences (Ellisville, MO, USA) and dis-
solved in water. For experiments involving IR exposure,
exponentially growing cells were treated with IR and
then incubated at 37°C for the indicated time before
analysis. For experiments involving treatment with both
NSC23766 and IR, cells were incubated with NSC23766
for 1 hour before IR exposure.
Antibodies and recombinant proteins
All antibodies were obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA), unless otherwise indi-
cated. These included mouse IgG for ATM (2C1)
(Novus Biologicals, Littleton, CO, USA), Cdc2 (17),
Chk1 (G-4), Chk2 (B-4), PARP (Ab-2) (EMD Bios-
ciences, San Jose, CA, USA), phospho-ERK1/2 (E-4);
rabbit IgG for ATM (Ab-3) (EMD Biosciences), Cdc2
(C-19), Chk1 (FL-476), Chk2 (Cell Signaling, Danvers,
MA, USA) MEK1/2 (12-B), Rac1 (C-14); and goat IgG
for Actin (I-19), ATR (N-19), phospho-Cdc2 (Tyr15),
ERK1/2 (C-14-G), and phospho-MEK1/2 (Ser118/
Ser122).
Recombinant PAK-1 protein for Rac1 activity assay
was obtained from Addgene (Cambridge, NH, USA) as a
glutathione S-transferase (GST) fusion protein contain-
ing full-length human PAK1 protein. Recombinant p53
protein for ATM and ATR kinase assays was a glu-
tathione S-transferase (GST) fusion protein containing
full-length human p53 (Addgene, Cambridge, MA,
USA). Recombinant Cdc25C protein, the substrate for
Chk1 and Chk2 kinase assay, was a GST fusion protein
containing residues 200 to 256 of human Cdc25C
(kindly provided by Dr. Helen Piwnica-Worms,
Washington University School of Medicine). All GST
fusion proteins were purified as described previously
[16]. GST was used as a control substrate in all kinase
assays and was prepared according to standard proce-
dures (GE Healthcare Bio-Sciences, Piscataway, NJ,
USA).
Immunoblotting, immunoprecipitation, and kinase assay
Immunoblotting, immunoprecipitation, and kinase
assays were performed as described previously
[16,37,38]. Specific protein signals on Western blots
were visualized by chemiluminescence exposed to x-ray
film, scanned by using EPSON Perfection 4490PHOTO
scanner, and analyzed by using the ImageJ analytical
program (NIH, Bethesda, MD, USA).
Rac1 activity assay
Rac1 activity was assayed by using a Rac1 assay kit
(Upstate Biotechnology, Lake Placid, NY, USA), as
described previously [39,40]. In brief, cells were lysed at
4°C in 25 mM HEPES buffer (pH 7.4) containing 10
mM MgCl2, 150 mM NaCl, 1% NP-40, 1 mM EDTA,
2% glycerol, 1 mM DTT, 1 μg/ml aprotinin, 1 μg/ml
leupeptin, 1 μg/ml pepstatin, 1 mM phenylmethylsulfo-
nyl fluoride, 1 mM sodium fluoride, and 1 mM sodium
vanadate. Cell lysates were incubated with GST-PAK1
fusion protein for 1 hour to capture GTP-bound Rac1.
The obtained GTP-bound Rac1 (Rac1-GTP) was
resolved on a 4% to 20% SDS-PAGE and assessed with
immunoblotting by using an anti-Rac1-specific antibody,
as described by the manufacturer’s instructions. As a
positive control, MCF-7 cells were serum-starved for 24
hours in the medium containing 0.3% fetal bovine
serum, treated with 1 μM phorbol 12-myristate 13-acet-
ate (PMA) for 5 minutes, and analyzed for Rac1 activity
[41].
Cell-cycle analysis
Fluorescence-activated cell sorting (FACS) analysis was
performed on 20,000 cells by using a FACS Calibur
instrument (Beckon Dickinson, Mansfield, MA, USA), as
described previously [16].
Analysis for mitotic cells
MCF-7 cells were exposed to IR in the presence/absence
Rac1-specific inhibitor NSC23766, harvested at the indi-
cated times, fixed in 70% ethanol, and stained with pro-
pidium iodide (PI) and anti-phospho-histone H3
antibody (Upstate Biotechnology, Lake Placid, NY, USA)
[12]. Mitotic cells, which contain both 4N-DNA content
and phospho-histone H3, were determined by using a
FACSCalibur instrument (Beckon Dickinson) and ana-
lyzed by using CELLQUEST software. Each analysis was
performed by using 20,000 cells.
The siRNAs and transfection
Short interfering RNA (siRNA) duplexes were obtained
from Dharmacon Research (Chicago, IL, USA). Control
nontargeting siRNA contains at least four mismatches
to any human, mouse, or rat gene, as previously deter-
mined by the manufacturer. The sequence for Control-
siRNA is 5’-UAAG GCUA UGAA GAGA UAC-3’.
SMARTpool siRNAs targeting Rac1 consist of four siR-
NAs targeting multiple sites on Rac1 (Rac1-siRNAs).
The sequences for Rac1-siRNAs are 5’-UAAG GAGA
UUGG UGCU GUA-3’, 5’-UAAA GACA CGAU CGAG
AAA-3’, 5’-CGGC ACCA CUGU CCCA ACA-3’, and
5’-AUGA AAGU GUCA CGGG UAA-3’.
Cells were transfected with siRNAs at 100 nM by
using DharmaFECT1 siRNA transfection reagent (Dhar-
macon Research, Chicago, IL, USA), according to the
manufacturer’s instruction. For experiments involving
both siRNA transfection and IR exposure, transfected
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cells were first incubated for the indicated times and
then exposed to IR.
Adenoviral vectors and adenoviral infections
Recombinant adenovirus N17Rac1 (Ad.N17Rac1) and
control adenovirus dl312 (Ad.Control) were kindly pro-
vided by Dr. Toren Finkel (NIH, Bethesda, MD, USA).
In Ad.N17Rac1, the Rac1 cDNA contains a Ser-to-Asp
substitution at position 17 and functions as a dominant-
negative mutant [42].
Log-phase MCF-7 cells were infected at 50 PFU/cell
with either Ad.N17Rac1 or Ad.Control for 24 hours
before exposure to IR, as described previously [43]. For
studies involving cell-cycle analysis, the cells were incu-
bated for additional 24 hours after IR and analyzed for
DNA content with flow cytometry [16]. For studies
involving mitotic cell analysis, the irradiated cells were
incubated for 2 hours and analyzed for cells containing
both 4N-DNA content and histone H3-Ser10 phosphor-
ylation [12].
DAPI staining
Apoptosis was assessed with 4’,6-diamidino-2-phenylin-
dole (DAPI) staining, as described previously [43].
Apoptotic cells were identified by condensation and
fragmentation of nuclei [44]. The percentage of viable
cells was calculated as the ratio of live cells to total cells
counted. At least 800 cells were counted per sample.
Cell-survival assay
Cell-survival assays were performed as described pre-
viously [45]. In brief, log-phase growing cells were
exposed to IR at the doses indicated, incubated for 7
days, and visualized for viable cells by staining with
crystal violet (Sigma-Aldrich, St. Louis, MO, USA). For
experiments involving treatment with both NSC23766
and IR, cells were preincubated for 1 hour with 100 μM
NSC23766, exposed to IR, and incubated for an addi-
tional 3 hours after IR. The cells were washed and incu-
bated in regular growth medium for 7 days before
analysis. The obtained sample dishes were scanned on
an EPSON Perfection 4490PHOTO scanner, and the
amount of cells remaining on the culture dish was
quantified by using the ImageJ analytic program.
Clonogenic assay
Clonogenic assay was performed as described previously
[46]. In brief, in the presence or absence of 100 μM
NSC23766, MCF-7 cells were exposed to IR at the doses
indicated and incubated for 3 hours after IR. The cells
were then rinsed with DMEM, reseeded at the cell num-
ber indicated in duplicate, and incubated for 10 to 14
days until colonies formed. The colonies were visualized
with crystal violet staining and quantified by using Ima-
geJ software, as described previously [47].
Results
IR exposure induces G2/M arrest and Rac1 GTPase
activation in MCF-7 breast cancer cells
To study the mechanisms regulating G2/M cell-cycle
checkpoint response after IR exposure, log-phase grow-
ing MCF-7 cells were exposed to IR at the indicated
doses and analyzed for DNA content at 8, 16, and 24
hours after IR. As shown in Figure 1A, IR exposure of
MCF-7 cells resulted in marked increase in amount of
4N-DNA content cells at 8 hours after IR, indicative of
G2/M arrest [3]. Furthermore, the strength of the G2/M
arrest detected at 8 hours after IR is independent of the
IR dose used. At 24 hours after irradiation, the percen-
tage of 4N-DNA content cells in the samples treated
with 5-Gy or 6.5-Gy was returned to baseline, whereas
the percentage of 4N-DNA content cells in the 10-Gy-
treated samples remained significantly above baseline.
We next quantified the amount of 4N-DNA content
cells in MCF-7 cells exposed to increasing doses of IR
and incubated for 24 hours. As shown in Figure 1B, at
24 hours after IR, the increase in amount of 4N-DNA
content cells in irradiated cells was dose dependent.
Samples exposed to 20-Gy IR and incubated for 24
hours revealed a fivefold increase in the amount of 4N-
DNA content cells compared with unirradiated control
cells (Figure 1B).
We next assessed the changes in Rac1 activity in cells
exposed to irradiation. As shown in Figure 1C, Rac1
activity was increased within 5 minutes after IR expo-
sure of MCF-7 cells. At 30 minutes after IR exposure,
an 18-fold increase in Rac1 activity was found in irra-
diated cells compared with control nonirradiated cells.
Furthermore, the increase in Rac1 activity was noted for
at least 1 hour after exposure to IR (data not shown).
Rac1 activation is required for IR-induced G2/M cell-cycle
arrest
By using a Rac1-specific inhibitor NSC23766 [36], we
examined the effect of Rac1 on IR-induced G2/M arrest.
For these experiments, MCF-7 cells were incubated for
1 hour in the presence of increasing doses of NSC23766
before exposure to 20-Gy IR. As shown in Figure 2A
(upper panel), preincubation of MCF-7 cells with 100
μM NSC23766 resulted in 90% inhibition in IR-induced
Rac1 activity (Rac1-GTP). As shown in Figure 2A (lower
panel), incubation of MCF-7 cells in the presence of 100
μM NSC23766 resulted in a near-complete inhibition in
IR-induced G2/M arrest (open bars). In contrast, incuba-
tion with NSC23766 alone in the absence of IR had only
a subtle, if any, effect on the percentage of 4N-DNA
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content cells relative to log-phase growing cells (Figure
2A, lower panel: solid bars). Furthermore, preincubation
of cells in the presence of 10 μM NSC23766, a dose that
did not inhibit Rac1 activity, had no effect on IR-
induced G2/M arrest (Figure 2A).
We next examined the effect of NSC23766 on the
induction of G2/M arrest over time. For these studies,
MCF-7 cells were exposed to 5-Gy or 10-Gy IR in the
presence or absence of 100 μM NSC23766, and the per-
centage of cells in G2/M phase was examined over time.
As shown in Figure 2B, treatment of cells with 5-Gy
and 10-Gy IR induced a marked increase in percentage
of cells with G2/M DNA content at 8 hours after irra-
diation. However, this IR-induced G2/M arrest was com-
pletely attenuated by incubation of cells in the presence
of Rac1 inhibitor NSC23766 (8 hours after IR, solid
circle and triangle versus open circle and triangle).
Furthermore, whereas 10-Gy-irradiated cells incubated
in the absence of Rac1 inhibitor showed a threefold
increase in percentage of G2/M DNA content cells at 24
hours after IR compared with control unirradiated cells,
cells exposed to 10-Gy IR and incubated in the presence
of NSC23766 showed no increase in the amount of G2/
M DNA-content cells compared with the control cells
(Figure 2B). Cells treated with NSC23766 alone in the
absence of IR showed no increase in amount of G2/M
DNA-content cells at all time points tested (open
square). These results suggest a requirement for Rac1
activity in IR-induced G2/M cell-cycle arrest.
To confirm the results obtained from MCF-7 cells, we
examined the effect of NSC23766 on IR-induced G2/M
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Figure 1 IR induces G2/M cell-cycle arrest and Rac1 activation in MCF-7 cells. (A) Upper panel: log-phase growing MCF-7 cells were
exposed to 5-Gy IR, incubated for the indicated hours, and analyzed for cell cycle by fluorescence-activated cell sorting (FACS). Amounts of cells
in the G1, S, and G2/M phases of the cell cycle are indicated. Lower panel: MCF-7 cells were exposed to IR at the dose indicated, incubated for
the indicated hours, and analyzed for DNA content. Results depict the percentage of cells with 4N-DNA content (G2/M phase) and represent the
mean ± SD of two sets of experiment in duplicate samples. *P = < 0.001 (n = 4), significant difference from control unirradiated cells. (B) Upper
panel: MCF-7 cells were exposed to IR at the indicated doses, incubated for 24 hours, and analyzed for cell cycle with FACS. Percentage of cells
in G1, S, and G2/M phases of the cell cycle are indicated. Lower panel: Cells were exposed to increasing doses of IR, incubated for 24 hours, and
analyzed for DNA content with FACS. Results depict the percentage of cells with 4N-DNA content and represent the mean ± SD of triplicate
samples. (C) MCF-7 cells were exposed to 20-Gy IR, incubated for the indicated times, and analyzed for Rac1 activity, as described in Materials
and methods.
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breast cancer cells. As shown in Figure 2C, preincubat-
ing each of these cells with 100 μM NSC23766 before
exposure to 10-Gy IR resulted in a marked attenuation
of the IR-induced G2/M cell-cycle arrest.
Because DNA damage-induced G2/M checkpoint acti-
vation involves phosphorylation of Cdc2-Tyr15 and con-
comitant inhibition of Cdc2 kinase activity [4-6], we
examined the effect of Rac1 inhibition on Cdc2-Tyr15
phosphorylation and Cdc2 activity in IR-treated cells. As
shown in Figure 3A, a marked increase was seen in
Cdc2-Tyr15 phosphorylation and inhibition of Cdc2
activity within 1 hour after IR exposure of MCF-7 cells.
Furthermore, the IR-induced increase in Cdc2-Tyr15
phosphorylation was completely inhibited by the incuba-
tion of cells with NSC23766 before IR exposure (Cdc2-
Tyr15), and this, in turn, resulted in a complete abroga-
tion of IR-caused inhibition of Cdc2 activity (Figure 3A,
Cdc2 activity). Thus, Rac1 activity is apparently
necessary for IR-induced Cdc2-Try15 phosphorylation
and inhibition of Cdc2 activity.
By using histone-H3 phosphorylation as a marker of
cells in mitosis [48], we examined the effect of Rac1 on
the proportion of cells in mitosis after IR exposure. As
shown in Figure 3B, IR exposure resulted in a rapid
decrease in the proportion of cells in mitosis in MCF-7
cells. At 2 hours after IR treatment of MCF-7 cells, an
approximate 90% decrease was noted in mitotic cells
relative to control nonirradiated cells (Figure 3B, solid
bars). In contrast, incubation of cells with NSC23766
blocked the effect of IR, resulting in a significant
increase in the proportion of mitotic cells in irradiated
cells compared with the control irradiated cells (Figure
3B, IR: open bar versus solid bar). Incubation of cells
with NSC23766 alone resulted in a slight increase in the
amount of mitotic cells compared with the control
untreated cells (Figure 3B, None: open bar versus solid
bar).
Rac1 inhibition abrogates IR-induced ATM and ATR
signaling activation
To investigate the mechanisms involved in the regula-
tion of IR-induced G2/M checkpoint activation by Rac1,
we examined the effect of Rac1 on IR-induced activation
of ATM and ATR signaling. For these studies, MCF-7
cells incubated in the presence or absence of NSC23766
were exposed to IR and then examined for the activities
of ATM, ATR, Chk1, and Chk2 kinases. As shown in
Figure 4A and 4B, incubation of MCF-7 cells with
NSC23766 before IR exposure resulted in marked
diminution of IR-induced activation of ATM, ATR,
Chk1, and Chk2 activities. To verify these effects by
Rac1 inhibition, MCF-7 cells were exposed to increasing
doses of IR in the presence or absence of NSC23766
and analyzed for Chk1 and Chk2 activities. As shown in
Figure 4C, whereas IR exposure of cells resulted in
dose-dependent increase in both Chk1 and Chk2 activ-
ities, the effect was markedly diminished by the presence
of Rac1 inhibition. Furthermore, as shown in Figure 4D,
NSC23766 preincubation also abrogated IR-induced
Chk1 and Chk2 activation in T47D and ZR-75-1 cells.
Inhibition of Rac1 by N17Rac1 dominant-negative mutant
or Rac1 siRNAs attenuates IR-induced G2/M checkpoint
activation
By using an adenoviral vector expressing N17Rac1
dominant-negative mutant [32], we further studied the
effect of Rac1 on IR-induced G2/M checkpoint response
in MCF-7 cells. As shown in Figure 5A (right panel
inset), Rac1 assay revealed a much lower Rac1 activity
in the irradiated cells expressing N17Rac1 mutant com-
pared with control irradiated cells (N17rac1 versus Con-
trol). We next examined the effect of N17Rac1 mutant
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Figure 2 Rac1 inhibition attenuates IR-induced G2/M arrest. (A)
Upper panel: MCF-7 cells were incubated for 1 hour with increasing
doses of the Rac1 inhibitor NSC23766 and then exposed to 20-Gy
IR. After 15-minute incubation at 37°C, Rac1 activity was determined.
As a positive control, MCF-7 cells were serum-starved for 24 hours
in the medium containing 0.3% fetal bovine serum, treated with 1
μM phorbol 12-myristate 13-acetate for 5 minutes, and analyzed for
Rac1 activity (PMA). Lower panel: MCF-7 cells were preincubated for
1 hour with NSC23766 at the indicated doses and treated with/
without 20-Gy IR. After 24-hour incubation after IR, the cells were
analyzed for DNA content with fluorescence-activated cell sorting
(FACS). Graph depicts the percentage of cells with 4N-DNA content
and represents the mean ± SD of quadruplicate samples. (B) MCF-7
cells were exposed to IR at the indicated doses in the presence or
absence of 100 μM NSC23766. After IR, the cells were incubated for
8 or 24 hours and analyzed for DNA content. Results depict the
percentage of cells with 4N-DNA content and represent the mean ±
SD of two separate experiments with duplicate samples. (C) Human
breast cancer cells (MDA-MB-231, T47D, ZR-75-1) were treated with
or without 10-Gy IR in the presence or absence of 100 μM
NSC23766, incubated for 24 hours, and analyzed for DNA content.
Results depict the percentage of cells with 4N-DNA content and
represent the mean ± SD of two sets of experiments in duplicate
samples.
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Figure 3 Rac1 inhibition abrogates IR-induced G2/M checkpoint activation. (A) MCF-7 cells were incubated for 1 hour in the presence or
absence of 100 μM NSC23766, treated with/without 20-Gy IR, and incubated for an additional 2 hours at 37°C. Cdc2 was immunoprecipitated
from cell lysates and analyzed for Cdc2-Tyr15 phosphorylation by immunoblotting (Cdc2-Tyr15) and Cdc2 activity by kinase assay (Cdc2 activity).
Amount of Cdc2 protein in the immunoprecipitates was assessed by immunoblotting (Cdc2 IP-WB). (B) Cells were treated as described and
analyzed for mitotic cells with fluorescence-activated cell sorting (FACS), which contains both 4N-DNA content and Histone H3-Ser10
phosphorylation, as described in Materials and methods. Upper panel: the histograms shown are representative FACS analyses for mitotic cells in
samples treated with/without IR in the presence or absence of NSC23766. The location of mitotic cells in each sample is indicated (M). Lower
panel: the bar graph depicts the percentage of mitotic cells and is shown as mean ± SD of triplicate samples. *P = < 0.001 (n = 3), significant
difference from cells exposed to IR in the absence of NSC23766.
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on IR-induced G2/M arrest in MCF-7 cells. As shown in
Figure 5A (left bar graph), FACS analyses revealed a
marked induction in IR-induced G2/M arrest in both
noninfected and Ad.Control-infected MCF-7 cells and
that this was blocked by the expression of N17Rac1
(N17Rac1 vs. Control, P < 0.001; n = 4). We also exam-
ined the effect of N17Rac1 on the proportion of mitotic
cells after IR exposure of MCF-7 cell. As shown in Fig-
ure 5A (right panel, bar graph), although a marked
decrease in proportion of mitotic cells was found in
both noninfected and Ad.Control-infected cells at 2
hours after IR, the expression of N17Rac1 apparently
blocked this effect of IR, resulting in a significant
increase in amount of mitotic cells compared with Ad.
Control-infected cells treated with IR (N17Rac1 vs. Con-
trol, P = 0.002; n = 3).
By using Rac1-specific siRNA, we examined the influ-
ence of Rac1 expression on the IR-induced G2/M check-
point response in MCF-7 cells. For these studies, MCF-7
cells were transfected with Rac1-specific siRNA or con-
trol nontargeting siRNA and incubated at 37°C for the
indicated times. As shown in Figure 5B (upper panel), a
77% reduction in Rac1 protein occurred at 2 days after
transfection of cells with Rac1 siRNA. In contrast, trans-
fection of MCF-7 cells with nontargeting control siRNA
had no effect on Rac1 protein levels relative to non-
transfected cells (Figure 5B, upper panel: Control versus
Log). To examine the effect of Rac1 on IR-induced G2/
M arrest, MCF-7 cells transfected with Rac1 or Control
siRNA were exposed to IR at the indicated doses and
analyzed for G2/M DNA content with FACS. As shown
in Figure 5B (lower panel), cells transfected with Rac1
siRNA revealed a marked attenuation in IR-induced G2/
M arrest compared with control siRNA-transfected cells
(open bars versus solid bars; P < 0.001; n = 6).
We next examined the effect of Rac1 on IR-induced
ATM and ATR signaling. As shown in Figure 5C, siRNA-
transfected MCF-7 cells exhibited a marked diminution in
the activation of ATM, ATR, Chk1, and Chk2 kinases
after IR exposure (ATM activity, Chk2 activity, ATR activ-
ity and Chk1 activity). In contrast, transfection of MCF-7
cells with control siRNA had no effect on IR-induced acti-
vation of ATM, ATR, Chk1 and Chk2 kinases compared
with nontransfected control cells (data not shown).
Rac1 inhibition abolishes IR-induced activation of MEK1/2
and ERK1/2
Previous studies from our laboratory demonstrated that
IR exposure of cells results in activation of ERK1/2 sig-
naling. Furthermore, IR-induced ERK1/2 signaling is
required for G2/M checkpoint activation after IR [16].
We therefore examined the effect of Rac1 on IR-induced
ERK1/2 signaling activation. For these studies, MCF-7
cells were incubated for 1 hour with increasing doses of
NSC23766 and then exposed to 20-Gy IR. At 15 min-
utes after IR, the cells were examined for MEK1/2 and
ERK1/2 phosphorylations by Western blot analysis. As
shown in Figure 6A, incubation of cells with Rac1 inhi-
bitor NSC23766 resulted in a dose-dependent diminu-
tion of IR-induced phosphorylation of both MEK1/2
and ERK1/2 (pMEK1/2 and pERK1/2). The maximal
diminution of IR-induced MEK1/2 and ERK1/2 phos-
phorylation occurred after incubation of cells with 100
μM NSC23766 (pMEK1/2 and pERK1/2). Furthermore,
these changes in phosphorylation of MEK1/2 and ERK1/
2 did not involve changes in levels of MEK1/2 and
ERK1/2 proteins (Figure 6A, MEK1/2 and ERK1/2).
With Rac1-specific siRNA, the effect of Rac1 expression
on IR-induced phosphorylation of MEK1/2 and ERK1/2
was also examined. As shown in Figure 6B, IR-induced
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Figure 4 Rac1 inhibition abolishes IR-induced activation of
both ATM and ATR signaling. (A) MCF-7 cells were treated with/
without 20-Gy IR in the presence or absence of 100 μM NSC23766
and incubated for 1 hour at 37°C before analysis. To assess the ATM
kinase activity, ATM was immunoprecipitated from cell lysate by
using anti-ATM antibody (2C1) and assayed for ATM activity by
using p53 recombinant protein as substrate. To measure the Chk2
activity, Chk2 was immunoprecipitated from cell lysate by using B-4
anti-Chk2 antibody and assayed for Chk2 activity by using Cdc25C
recombinant protein as substrate. As controls, ATM and Chk2
protein levels in the immunoprecipitates (IP-WB) as well as in cell
lysates (WB) were assessed with immunoblotting. (B) ATR and Chk1
were immunoprecipitated from cell lysates by using N-19 anti-ATR
and G-4 anti-Chk1 antibody, respectively. ATR activity was assayed
by using p53 recombinant protein substrate, and Chk1 activity
assayed by using Cdc25C recombinant protein substrate. As
controls, ATR and Chk1 protein levels in the immunoprecipitates (IP-
WB), as well as in cell lysates (WB) were assessed with
immunoblotting. (C) MCF-7 cells were exposed to IR at the
indicated doses in the presence or absence of NSC23766, incubated
for 1 hour, and assessed for Chk1 and Chk2 activities. *Kinase assay
does not contain Cdc25C substrate. (D) T47D and ZR-75-1 cells
were exposed to 10-Gy IR in the presence or absence of 100 μM
NSC23766, incubated for 1 hour, and analyzed for Chk1 and Chk2
activities.
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phosphorylation of MEK1/2 and ERK1/2 was attenuated
in Rac1 siRNA-transfected cells, but not in control siRNA-
transfected cells (pMEK1/2 and pERK1/2).
Inhibition of Rac1 sensitizes MCF-7 cells to IR exposure
As shown in Figures 1 through 5, although IR exposure
induced G2/M cell-cycle arrest in human breast cancer
cells, this effect of IR was markedly attenuated by the
Rac1 inhibition. We therefore examined the effect of
Rac1 on cell survival after IR exposure. As shown in Fig-
ure 7A, IR exposure of MCF-7 cells resulted in dose-
dependent decrease in the amount of cells remaining on
the culture dish at 7 days after irradiation. Furthermore,
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Figure 5 Inhibition of Rac1 by N17Rac1 mutant or Rac1 siRNA diminishes IR-induced G2/M checkpoint activation. (A) MCF-7 cells were
infected with Ad.N17Rac1 or Ad.Control for 24 hours and exposed to 15-Gy IR. Left panel: the cells were analyzed for DNA content 24 hours
after IR. The result depicts the percentage of cells with 4N-DNA content and is shown as mean ± SD of quadruplicate samples. *P < 0.001 (n =
4), significant difference from the irradiated Ad.Control-infected cells. Right panel: Inset: at 15 minutes after IR, the infected cells were analyzed
for Rac1 activities (Rac1-GTP) and protein levels (total Rac1). Bar graph: mitotic cells in the cell samples were analyzed 2 hours after IR. The result
depicts the percentage of mitotic cells and is shown as mean ± SD of triplicate samples. **P = 0.002 (n = 3), significant difference from the
irradiated Ad.Control-infected cells. (B) Upper panel: MCF-7 cells transfected with Rac1 siRNA (Rac1) or control siRNA (Control) were incubated for
the indicated times and analyzed for protein levels of Rac1 and Actin. Lower panel: After 2-day incubation, the siRNA-transfected cells were
exposed to IR, incubated for 24 hours, and assessed for DNA content. Results depict the percentage of cells with 4N-DNA content and represent
the mean ± SD of three separate experiments in duplicate samples. *P < 0.001 (n = 6), significant difference from the irradiated Control-siRNA
transfected cells. (C) After 2-day incubation, siRNA-transfected cells were treated with/without 20-Gy IR, incubated for 1 hour, and analyzed for
ATM, ATR, Chk1, and Chk2 activities.
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resulted in a further decrease in the amount of cells
remaining on the culture dish compared with the sam-
ples treated with IR only (Figure 7A). As shown in Fig-
ure 7A (right panel), samples exposed to IR in the
presence of NSC23766 revealed an additional > 60%
decrease in the amount of cells remaining on the culture
dish compared with samples exposed to the same dose
of IR in the absence of NSC23766. In contrast, samples
treated with NSC23766 alone in the absence of IR treat-
ment had no effect on the amount of cells on a culture
dish compared with control untreated samples (Figure
7A).
A parallel set of cell samples described earlier was also
examined for morphology by using phase-contrast
microscopy. As shown in Figure 7B, after 7-day incuba-
tion after IR, whereas cells treated with IR alone
remained attached to the dish, cells exposed to IR in the
presence of NSC23766 rounded up. These results are
consistent with those presented in Figure 7A, suggesting
that inhibition of Rac1 reduces the survival of MCF-7
cells after IR exposure.
To investigate the possible mechanism involved in the
effect of Rac1 inhibition on cell survival after IR expo-
sure, we assessed the integrity of PARP in cells exposed
to IR in the presence or absence of NSC23766. Previous
studies have shown that the cleavage of PARP, a hall-
mark of apoptosis, occurs during the execution phase of
programmed cell death [49]. As shown in Figure 7C,
exposure to increasing doses of IR in the absence of
NSC23766 had no detectable effect on the levels of
intact PARP in MCF-7 cells, determined at 3 days after
IR (Figure 7C, upper panel). In contrast, exposure of
cells to IR in the presence of NSC23766 resulted in a
marked decrease in levels of intact PARP. These results
suggest that the increase in sensitivity of MCF-7 cells to
irradiation by NSC23766 involves induction of
apoptosis.
Discussion
G2/M transition of the cell cycle is tightly controlled
by the activity of the Cdc2/cyclin B complex, which is
required for cell entry into mitosis. It has previously
been shown that DNA damage induces phosphoryla-
tion of Cdc2-Tyr15, resulting in inhibition of Cdc2/
cyclin B activity and ultimately G2/M arrest [3]. The
results in this report indicate that IR exposure of
MCF-7 cells induces Rac1 activation (see Figure 1C).
Furthermore, inhibition of Rac1 by using the specific
inhibitor, dominant-negative mutant Rac1 or specific
Rac1 siRNA markedly attenuates IR-induced G2/M
arrest (see Figures 2 and 5). Additional studies in this
report indicate that the inhibition of IR-induced Rac1
activation abolishes IR-induced activation of Chk1 and
Chk2 kinases (see Figures 4 and 5) and subsequent
Cdc2-Tyr15 phosphorylation (see Figure 3A). Because
previous studies indicate that the transition of cells
from G2 to M phase of the cell cycle requires Cdc2/
cyclin B activity, we also assessed the effect of Rac1
inhibition on the proportion of cells in mitosis. The
studies presented in Figures 3B and 5A indicate that
IR exposure of log-phase growing MCF-7 cells results
in a marked decrease in mitotic cells within 2 hours
after IR, and that this effect is significantly inhibited by
the incubation of cells with NSC23766 or expression
of the N17Rac1 dominant-negative mutant. Thus, Rac1
inhibition diminishes IR-induced G2/M checkpoint
activation and increases the entry of cells from G2 into
M phase of the cell cycle in MCF-7 cells exposed to
IR. These studies suggest Rac1 as an upstream regula-
tor of G2/M checkpoint response after exposure of
cells to IR.
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Figure 6 Rac1 inhibition abolishes IR-induced activation of
MEK1/2 and ERK1/2. (A) MCF-7 cells were incubated with
increasing doses of NSC23766 for 1 hour at 37°C, exposed to 20-Gy
IR, and incubated for additional 15 minutes. The cells were analyzed
with immunoblotting for levels of phospho-MEK1/2 (pMEK1/2),
phospho-ERK1/2 (pERK1/2), total MEK1/2 (MEK1/2), total ERK1/2
(ERK1/2), and Actin (Actin). (B) Cells were transfected with control or
Rac1 siRNA, incubated for 2 days, and then exposed to 20-Gy IR or
left nonirradiated. After incubation for 15 minutes at 37°C, the cells
were examined for levels of phospho-MEK1/2, phospho-ERK1/2, total
MEK1/2, total ERK1/2, and actin.
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Cellular response to IR-induced DNA damage involves
activation of ATM and ATR signaling, which results in
activation of the Wee1 kinase that phosphorylates Cdc2-
Tyr15 and inhibition of the Cdc25 phosphatase that
dephosphorylates Cdc2-Tyr15 [50,51]. Although it still
remains unclear how exactly the ATM and ATR kinases
are activated in response to genotoxic stress, evidence
suggests that multiple mechanisms might be involved in
the regulation of this biologic process. Supporting this
speculation, a recent study by Wang et al. [52] reported
that the p38MAPK pathway is required for the activa-
tion of ATR kinase after expression of hepatitis B virus
X protein.
Another example is NBS1, a component of the
MRE11/RAD50/NBS1 complex, which not only is
involved in certain downstream steps of ATM- and
ATR-dependent DNA damage response but also func-
tions as an upstream mediator required for the ATM
and ATR signaling activation after IR-induced DNA
damage [53]. The results from the present report sug-
gest that Rac1 also plays an important role in the activa-
tion of ATM and ATR signaling after IR exposure of
cells (see Figures 4 and 5).
A previous study demonstrated that incubation of
MCF-7 cells with Rac1 specific inhibitor NSC23766 at
100 μM for 48 hours results in a G1 cell-cycle arrest
[54]. However, in the present studies, we observe that
incubation of MCF-7 cells with 100 μM NSC23766 for
up to 24 hours does not result in a detectable increase
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Figure 7 Inhibition of Rac1 sensitizes MCF-7 cells to irradiation. (A) MCF-7 cells were exposed to increasing doses of IR in the presence or
absence of 100 μM NSC23766 and incubated for 3 hours after IR. The cells were washed, incubated in regular growth medium for 7 days, and
analyzed for viable cells with crystal violet staining. Left panel: representative sample dishes stained with crystal violet. Right panel: amount of
viable cells in each sample was quantified with the ImageJ analytic program, and the results expressed as the mean ± SD of triplicate samples
(right panel). *P = < 0.001 (n = 3). (B) A parallel set of cell samples from this treatment were photographed by using phase-contrast optics. (C)
Upper panel: cells were exposed to IR at the indicated doses, incubated for 3 days, and analyzed for levels of full-length PARP by
immunoblotting (PARP). As a control, Actin levels in cell lysates were assessed with immunoblotting (actin). Lower panel: cells exposed to 10-Gy
IR in the presence or absence of NSC23766 were incubated for 3 days and analyzed for levels of full-length PARP (PARP) and actin (actin) with
immunoblotting.
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Additional file 1, Figure S1). Furthermore, incubation of
other cells, including MDA-MB-231, T47D, and ZR-75-
1, with 100 μM NSC23766 for up to 24 hours, also does
not result in an increase in percentage of G1-phase cells
(data not shown). Thus, the effect of NSC23766 on G1-
phase cells is probably time dependent. Additional stu-
dies are needed to understand the effect of prolonged
Rac1 inhibition on cell-cycle regulation in log-phase
growing cells.
Expression of N17Rac1 dominant-negative mutant for
72 hours has been previously shown to result in G2/M
cell-cycle arrest in Rat 2 fibroblast cells [32]. In the pre-
sent studies, after 24-hour expression of N17Rac1, we
do not observe any noticeable effect by N17Rac1 on the
proportion of G2/M phase cells in log-phase growing
MCF-7 cells (data not shown). Thus, the effect of
N17Rac1 on G2/M phase cells is probably cell-type spe-
cific and/or time dependent. In contrast, expression of
N17Rac1 in MCF-7 cells abrogates the IR-induced acti-
vation of Rac1, and this, in turn, is associated with an
attenuation of G2/M arrest in irradiated cells and an
increase in the amount of mitotic cells after irradiation
(see Figure 5A).
Previous studies from several laboratories, including
our own, have suggested an important role for ERK1/2
signaling in the activation of the G2/M checkpoint
response after DNA damage [16,20,21]. These studies
have demonstrated that DNA damage induces ERK1/2
activation and that this is associated with the induction
of G2/M arrest. Additional studies demonstrate that
inhibition of ERK1/2 abrogates the G2/M checkpoint
response after DNA damage, resulting in increased sen-
sitivity of cells to DNA-damaging agents [16,20,21].
Results presented in this report indicate that Rac1 inhi-
bition after incubation of cells with a specific inhibitor
or transfection with Rac1-specific siRNA abrogates IR-
induced phosphorylation of MEK1/2 and ERK1/2 (see
Figure 6), as well as the IR-induced G2/M checkpoint
activation (see Figures 2 through 5), suggesting Rac1 as
the upstream regulator of IR-induced ERK1/2 signaling.
A role for p53 in the regulation of the G2/M check-
point response has been suggested by previous studies,
as several of the transcriptional targets of p53 can
directly or indirectly inhibit Cdc2 kinase, which include
p21Waf1/Cip1, 14-3-3s, and Gadd45 [55]. However, the
results of this report suggest that IR-induced G2/M cell-
cycle arrest as well as the regulation of Rac1 on the IR-
induced G2/M checkpoint response is apparently inde-
pendent of p53, as among the four breast cancer cell
lines used for the studies, MDA-MB-231 and T47D cells
express mutant p53 [56], whereas MCF-7 and ZR75-1
express wild-type p53. Consistent with our observation,
results from other studies also show that p53 status has
no influence on IR-induced G2/M cycle arrest [57].
The results in Figures 2 through 5 show that IR-
induced G2/M arrest in human breast cancer cells is
markedly attenuated by the inhibition of Rac1. Further-
more, the results in Figure 7 and Additional file 1, Fig-
ure S4, provide evidence that Rac1 inhibition
significantly increases the sensitivity of MCF-7 cells to
irradiation, which involves apoptosis induction. These
results suggest a strong correlation between the attenua-
tion of G2/M arrest and the increased radiation sensitiv-
ity in MCF-7 cells treated with IR in the presence of
Rac1 inhibition. It is possible that the increased radia-
tion sensitivity is simply a consequence of the attenua-
tion of IR-induced G2/M arrest by Rac1 inhibition.
However, it could also be due to a new function of
Rac1. Future studies must address this question.
In this report, we also tested the effect of Rac1 inhibi-
tion on IR-induced G2/M arrest in normal human mam-
mary epithelial cells (MCF-10A and 76N). The results
are unexpected, as the Rac1 inhibition by NSC23766
does not block the IR-induced G2/M arrest in these
cells (see Additional file 1, Figure S5), whereas it blocks
completely the IR-induced G2/M arrest in human breast
cancer cells (see Figures 2 through 5). The mechanism
causing this difference is unclear. However, it should be
noted that the growth medium DFCI-1 used for the
normal human mammary epithelial cells contains addi-
tional growth factors that are not presented in the med-
ium for maintaining the breast cancer cells, which
include EGF, estradiol, and insulin (see Materials and
methods). It might be that these additional components
in DFCI-1 growth medium compensate for the effect of
Rac1 inhibition on IR-induced G2/M checkpoint activa-
tion. We will investigate this possibility in future studies.
Previous studies from our laboratory demonstrate that
inhibition of ERK1/2 by MEK1/2 specific inhibitors or
decreased ERK1/2 expression by transfection of cells
with ERK1/2 siRNA abrogated the IR-induced ATR acti-
vation in MCF-7 cells but had little effect on ATM acti-
vation [16]. Furthermore, additional studies demonstrate
that ERK1/2 signaling is upstream of ATR, as decreased
ATR expression in MCF-7 cells after transfection with
ATR siRNA or incubation of cells with caffeine, which
inhibits both ATR and ATM, has no effect on IR-
induced ERK1/2 activation [16]. Results presented in
this study indicate that Rac1 activation not only is
necessary for the activation of ERK1/2 and ATR kinases,
but also is essential for the activation of ATM signaling
after IR exposure (Figures 4 and 5).
A growing amount of evidence shows that IR exposure
of breast cancer cells frequently results in G2/M cell-
cycle arrest [58], and induction of cell-cycle arrest after
DNA damage has been associated with DNA repair and
cell survival [50,59,60]. Thus, a better understanding of
the mechanisms responsible for IR-induced G2/M cell-
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cycle arrest would potentially allow identifying novel
therapeutic targets that could be exploited to sensitize
breast cancer cells to radiation treatment.
Results in this report provide evidence supporting a
novel role for Rac1 in the activation of G2/M checkpoint
response and promotion of cell survival after IR
exposure.
Conclusions
IR exposure of MCF-7 breast cancer cells was associated
with a rapid activation of Rac1 and an induction of G2/
M cell cycle arrest. Furthermore, inhibition of Rac1 by
using specific inhibitor, dominant-negative mutant Rac1
or specific siRNA diminished IR-induced activation of
ATM and ATR signaling and attenuated IR-induced G2/
M cell cycle arrest. Moreover, inhibition of Rac1 mark-
edly increased the sensitivity of MCF-7 cells to IR expo-
sure, which involves induction of apoptosis. Collectively,
results in this report suggest an important role of Rac1
in the activation of the G2/M checkpoint response and
cell survival after IR exposure.
Additional material
Additional file 1: Figure S1. Effect of NSC23766 on cell cycle after IR
exposure of MCF-7 cells. Figure S2. Incubation with NSC23766 did not
result in apoptosis induction in MCF-7 cells. Figure S3. Treatment with
NSC23766 had no effect on clonogenic survival of MCF-7 cells. Figure
S4. Inhibition of Rac1 by NSC23766 decreased the ability of irradiated
MCF-7 cells to grow colonies. Figure S5. Inhibition of Rac1 by NSC23766
had no effect on IR-induced G2/M arrest in normal human mammary
epithelial cells.
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